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Abstract
For peptide receptor targeting usually internalizing agonists are selected. There is increasing 
evidence that non-internalizing receptor antagonists can be used for this purpose. We investigated 
whether the glucagon-like peptide-1 receptor (GLP-1R) antagonist exendin(9-39) can be used for 
in vivo targeting of GLP-1R expressing tumours and compared the in vitro and in vivo 
characteristics to the GLP-1R agonists exendin-3 and exendin-4.
The binding and internalization kinetics of labelled [Lys40(DTPA)]exendin-3, 
[Lys40(DTPA)]exendin-4 and [Lys40(DTPA)]exendin(9-39) were determined in vitro using INS-1 
cells. The in vivo targeting properties of [Lys40(111In-DTPA)]exendin-3, [Lys40(111In-
DTPA)]exendin-4 and [Lys40(111In-DTPA)]exendin(9-39) were examined in BALB/c nude mice 
with subcutaneous INS-1 tumours. natIn-labelled [Lys40(DTPA)]exendin-3, 
[Lys40(DTPA)]exendin-4 and [Lys40(DTPA)]exendin(9-39) exhibited similar IC50 values (13.5, 
14.4 and 13.4 nM, respectively) and bound to 26 × 103, 41 × 103 and 37 × 103 receptors/cell, 
respectively. [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In-DTPA)]exendin-4 showed rapid in 
vitro binding and internalization kinetics, whereas [Lys40(111In-DTPA)]exendin(9-39) showed 
lower binding and minimal internalization in vitro. In mice, high specific uptake of [Lys40(111In-
DTPA)]exendin-3 (25.0 ± 6.0 %ID/g) in the tumour was observed at 0.5 h p.i. with similar uptake 
up to 4 h p.i.. [Lys40(111In-DTPA)]exendin-4 showed higher tumour uptake at 1 and 4 h p.i. (40.8 
± 7.0 and 41.9 ± 7.2 %ID/g, respectively). Remarkably, [Lys40(111In-DTPA)]exendin(9-39) 
showed only low specific uptake in the tumour at 0.5 h p.i. (3.2 ± 0.7 %ID/g), rapidly decreasing 
over time.
In conclusion, the GLP-1R agonists [Lys40(DTPA)]exendin-3 and [Lys40(DTPA)]exendin-4 
labelled with 111In could be useful for in vivo GLP-1R targeting, whereas 
[Lys40(DTPA)]exendin(9-39) is not suited for in vivo targeting of the GLP-1R.
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Introduction
Peptide receptor targeting is a successful method for the diagnosis and therapy of 
neuroendocrine tumours (NET) (1) with somatostatin receptor targeting as the most 
successful example. In general, agonists are selected for receptor targeting, because agonists 
usually trigger the internalization of the ligand-receptor complex (2). Internalization of the 
ligand-receptor complex is the basis for increasing target-to-background ratios, due to 
retention of the radiolabelled tracer in the target tissue through metabolic trapping (1,3–6). 
Therefore, internalization is considered to be a crucial step for in vivo peptide receptor 
targeting (5,6). A correlation between internalization rate and in vivo accumulation of 
radiolabelled somatostatin analogues in somatostatin receptor subtype 2 (sstr2) has been 
found in rats with AR42J tumours (7).
Most peptide receptor antagonist do not internalize, while they do bind to the same receptor 
with high affinity. Antagonists were considered not be suitable for in vivo imaging of 
tumours due to the lack of internalization. This has been supported by several studies, for 
example a study showing that a bombesin agonist displayed superior in vivo targeting 
characteristics in comparison to the antagonist (8). However, recent studies showed 
favourable in vivo targeting of radiolabelled bombesin antagonists with higher tumour 
uptake and longer washout compared to bombesin agonists (9–11). Moreover, a recent study 
with somatostatin receptor type 2 (sstr 2) and type 3 (sstr 3) ligands showed a remarkably 
higher uptake in the tumour of the antagonists than the agonists (12). Therefore, there is 
increasing evidence that peptide receptor antagonists may be useful for the in vivo targeting 
of receptor expressing tissues.
Insulinomas are NET derived from pancreatic beta cells. Although somatostatin receptor 
scintigraphy is highly efficient in detecting NET and their metastases (13), the sensitivity for 
the detection of insulinomas is only 40–60% caused by a relatively low incidence of sstr2 
and sstr5 receptor subtype expression in insulinomas (13–15). In comparison, the glucacon-
like peptide-1 receptor (GLP-1R) is expressed on more than 90% of insulinomas and at a 
mean density that is two times higher than that of the sst2r (16). Exendin is a GLP-1 
(glucagon-like peptide-1) analogue that targets the GLP-1R. For the detection of 
insulinomas, radiolabelled exendin has been developed recently, with promising preclinical 
as well as clinical results (17–20). Therefore, exendin analogues should be considered for 
insulinoma targeting (17–21).
For the targeting of the GLP-1R, only agonists (exendin-3 and exendin-4) labelled 
with 111In via DTPA conjugated to a C-terminal lysine residue have been examined 
(17,18,20–22). The GLP-1R antagonist exendin(9-39) is an amino-terminally truncated 
variant prepared by enzymatic degradation of exendin (Table 1). We aimed to investigate 
whether exendin(9-39) may also be suitable or – in analogy to the sstr2, sstr3 and bombesin 
antagonists (9–12) – may even be superior for insulinoma imaging as compared to exendin 3 
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and 4. Therefore, we investigated the in vitro and in vivo GLP-1R targeting characteristics of 
the GLP-1R antagonist exendin(9-39) conjugated with DTPA at a C-terminal Lysine: 
[Lys40(DTPA)]exendin(9-39) and compared these with these of agonists 
[Lys40(DTPA)]exendin-3 and [Lys40(DTPA)]exendin-4.
Results
Radiolabelling
All peptides could be labelled with 111In with a specific activity of up to 700 GBq/μmol. 
Radiochemical purity was >99% as determined by HPLC and ITLC. 111In-EDTA eluted 
from the column after 3 min whereas 111In-labelled [Lys40(DTPA)]exendin-3, 
[Lys40(DTPA)]exendin-4 and [Lys40(DTPA)]exendin(9-39) had a retention time of ~13 
min.
Receptor binding assays
The results of the IC50 determination are shown in Figure 1 and Table 2. The IC50 of natIn-
labelled [Lys40(DTPA)]exendin-3, [Lys40(DTPA)]exendin-4 and 
[Lys40(DTPA)]exendin(9-39) were 13.5 nM, 13.4 nM and 14.4 nM, respectively.
The results of the saturation binding assay are summarized in Figure 2 and Table 2. 
[Lys40(111In-DTPA)]exendin-3 bound 26,000 receptors/cell, [Lys40(111In-DTPA)]exendin-4 
bound 41,000 receptors/cell and [Lys40(111In-DTPA)]exendin(9-39) bound 37,000 
receptors/cell. The Kd for [Lys40(111In-DTPA)]exendin-3, [Lys40(111In-DTPA)]exendin-4 
and [Lys40(111In-DTPA)]exendin(9-39) was 8.7 nM, 17.6 nM and 15.1 nM, respectively.
The large standard deviation for the Kd and Bmax for [Lys40(111In-DTPA)]exendin(9-39) is 
due to the lower in vitro binding of this tracer, resulting in a low signal in this assay. This 
finding is in line with the results reported by Waser et al., which also showed lower in vitro 
binding of exendin(9-39) (23).
Internalization assay
The internalization kinetics of [Lys40(111In-DTPA)]exendin-3, [Lys40(111In-
DTPA)]exendin-4 and [Lys40(111In-DTPA)]exendin(9-39) are shown in Figure 3. After 0.5 
hour 1.1 ± 0.1 fmol [Lys40(111In-DTPA)]exendin-3 was bound to the receptor and 1.1 ± 0.2 
fmol was internalized, increasing to 3.3 ± 0.2 fmol cell bound and 1.6 ± 0.1 fmol 
internalized after 4 hours. The binding kinetics of [Lys40(111In-DTPA)]exendin-4 were 
similar to that of [Lys40(111In-DTPA)]exendin-3, with maximum binding and internalization 
after 4 hours: 4.2 ± 0.2 fmol and 2.1 ± 0.2 fmol, respectively. Membrane bound 
[Lys40(111In-DTPA)]exendin(9-39) after 0.5 h was 0.9 ± 0.3 fmol and decreased to 0.4 ±0.1 
fmol after 4 h. Minimal internalization of [Lys40(111In-DTPA)]exendin(9-39) was observed
Biodistribution studies
The results of the biodistribution studies are summarized in Figure 4. [Lys40(111In-
DTPA)]exendin-3 showed high uptake in the tumour as soon as 30 min after injection (25.0 
± 6.0 %ID/g) and a similar uptake was observed up to 4 h p.i. (26.5 ± 8.9 %ID/g). There was 
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no significant difference in tumour uptake between any time points. Co-administration of an 
excess unlabelled exendin resulted in much lower uptake: 2.4 ± 0.5 %ID/g, indicating that 
the uptake was GLP-1R-mediated. Specific uptake of [Lys40(111In-DTPA)]exendin-3 was 
also seen in pancreas, lung and stomach. [Lys40(111In-DTPA)]exendin-4 showed a higher 
tumour uptake: 30.7 ± 6.1 %ID/g at 0.5 h p.i. increasing to 41.9 ± 7.2 %ID/g at 4 h p.i. and 
was statistically higher than tumour uptake of [Lys40(111In-DTPA)]exendin-3 at 1 and 4 h 
p.i. (p = 0.04 and 0.02, respectively). There was no significant difference in pancreas, 
stomach and lung uptake between [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In-
DTPA)]exendin-4. In contrast, [Lys40(111In-DTPA)]exendin(9-39) showed much lower 
uptake in the tumour at 0.5 h p.i.: 3.2 ± 0.7 %ID/g and there was a rapid wash-out of 
[Lys40(111In-DTPA)]exendin(9-39) from the tumour. The same phenomenon was found in 
all GLP-1R positive organs (pancreas, lung, stomach and duodenum).
Renal uptake was significantly higher with [Lys40(111In-DTPA)]exendin-3 and 
[Lys40(111In-DTPA)]exendin-4 compared to renal uptake of [Lys40(111In-
DTPA)]exendin(9-39) (p=0.0003 and p=0.0002 respectively).
Discussion
In this study, the tumour targeting characteristics of the GLP-1 receptor (GLP-1R) 
antagonist exendin(9-39) and the agonists exendin-3 and exendin-4 were evaluated in vitro 
and in vivo. We found that [Lys40(natIn-DTPA)]exendin(9-39) had a similar affinity for the 
GLP-1R as the agonists [Lys40(natIn-DTPA)]exendin-3 and [Lys40(natIn-DTPA)]exendin-4, 
as determined in the IC50 assay. [Lys40(111In-DTPA)]exendin(9-39) bound to a similar 
number of receptors per cell in vitro as compared to the 111In-labelled agonists. The results 
of the IC50 determination and the Scatchard analysis of exendin-3 were paradoxal: the IC50 
of exendin-3 (13.5 nM) was significantly higher than the Kd as derived from the Scatchard 
analysis (8.7 nM). This could be due to the fact that in the Scatchard analysis 111In-labelled 
exendin-3 was used, while in the IC50 nonradioactive exendin-3 was used.
Despite the high affinity, [Lys40(111In-DTPA)]exendin(9-39) showed lower in vitro binding 
compared to the agonists and minimal internalization as compared to the agonists. The 
biodistribution study showed high uptake of the agonists in the tumour and in GLP-1R 
positive organs (pancreas, lung and stomach). In contrast, [Lys40(111In-
DTPA)]exendin(9-39) showed much lower uptake in GLP-1R expressing tissues at 0.5 h p.i. 
and the uptake rapidly decreased at later time points. These results suggest that 
internalization is a prerequisite for specific accumulation of the ligand in GLP-1R 
expressing tissues in vitro and in vivo.
Previous studies showed favourable tumour targeting of antagonists compared to agonists, 
that could be explained by the fact that the antagonists bound to more receptors than the 
agonists (9,12,24,25). In our study there was no significant difference between the number 
of receptors bound by [Lys40(111In-DTPA)]exendin(9-39) and agonists [Lys40(111In-
DTPA)]exendin-3 and [Lys40(111In-DTPA)]exendin-4. Our study showed that [Lys40(111In-
DTPA)]exendin(9-39) is not suitable for the targeting of the GLP-1R in vivo. A recent study 
evaluated the potency of 125I-exendin(9-39) for pancreatic beta cell imaging and showed 
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high uptake in the pancreas (approximately 20% ID/g) of ddY mice (26). A difference 
between the two studies is the peptide dose injected. We have previously shown that the 
optimal peptide dose for the GLP-1R agonist [Lys40(111In-DTPA)]exendin-3 in BALB/c 
nude mice with a subcutaneous tumour model is < 0.1μg (27). The peptide dose of 125I-
exendin(9-39) was 60-fold lower than the peptide dose in our study (0.0017 μg vs. 0.1 μg), 
which might explain the enhanced pancreatic uptake of 125I-exendin(9-39). A straight 
comparison between the two tracers is needed to clarify the cause of the paradoxal results in 
the two studies. Although high pancreatic uptake was observed of 125I-exendin(9-39), the 
feasibility for beta-cell imaging remains to be determined, because for imaging purposes 
higher activity doses and thus higher peptide doses will be required.
By in vitro autoradiography Waser et al. found that 125I-exendin(9-39) had a high affinity 
for the GLP-1R in murine pancreatic tissue (2.6 ± 0.4 nM), whereas the affinity for the 
human GLP-1R is much lower (63 ± 47 nM) (28). It should be noted that this study does not 
provide data to show that GLP-1R antagonists are superior or inferior to GLP-1R agonists.
Our biodistribution study showed high uptake for all peptides in the kidney, which was not 
GLP-1R-mediated. The renal uptake of the radiolabelled tracer is caused by tubular 
reabsorbtion after glomerular filtration. The renal uptake of [Lys40(111In-
DTPA)]exendin(9-39) was significantly lower than that of [Lys40(111In-DTPA)]exendin-3 
and [Lys40(111In-DTPA)]exendin-4, indicating that the 8 N-terminal amino acid sequence 
caused more efficient tubular reabsorption. Another explanation might be a different uptake 
mechanism of [Lys40(111In-DTPA)]exendin(9-39) and [Lys40(111In-DTPA)]exendin-3 and 
[Lys40(111In-DTPA)]exendin-4 in the proximal tubules of the kidney.
Conclusion
The GLP-1R agonists exendin-3 and exendin-4 show high receptor affinity and efficient in 
vitro binding and internalization kinetics. [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In-
DTPA)]exendin-4 accumulated efficiently in INS-1 tumours and GLP-1R positive organs 
and could therefore be useful for detection and therapy of insulinomas. 
[Lys40(DTPA)]exendin(9-39) exhibited high affinity for the GLP-1R, but did not show 
internalization and low uptake in INS-1 tumours and GLP-1R positive organs and therefore 
is not suited for targeting the GLP-1R in vivo. This study indicates that internalization is 
crucial for efficient accumulation and retention in GLP-1R positive tissues.
Experimental
Radiolabelling of exendin
[Lys40(DTPA)]exendin-3, [Lys40(DTPA)]exendin-4 and [Lys40(DTPA)]exendin(9-39) were 
purchased from Peptide Specialty Laboratories (Heidelberg, Germany). Labelling of DTPA-
conjugated [Lys40]exendin-3, [Lys40]exendin-4 or [Lys40]exendin(9-39) was performed 
under identical conditions. 150 MBq 111InCl3 was added to 1 μg of exendin in 5 volumes of 
0.1 M MES buffer, pH 5.5. After 30 min of incubation at room temperature, EDTA was 
added to a final concentration of 5 mM and incubated at room temperature for 5 min. 
Tween80 was added to a final concentration of 0.1% and quality control was performed 
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using reversed-phase high performance liquid chromatography (RP-HPLC) on a C18 
reversed-phase column (Zorbax Rx-C18; 4.6 mm × 25 cm; Agilent echnologies). The 
column was eluted with 10 mM NH4Ac, pH 5.5 with a linear gradient to 100% acetonitrile 
over 10 min with a flow rate of 1 ml/min.
ITLC was performed on silica gel ITLC strips (Pall Corporation Life Sciences, New York, 
NY, USA). Two mobile phases were used: 0.1 M EDTA in 0.1 M NH4Ac, pH 5.5 (Rf 111In-
labelled exendin = 0, Rf 111In-EDTA = 1) and 0.25 M NH4Ac, pH 5.5:methanol (1:1) (Rf 
colloidal residues = 0, Rf 111In-labelled [Lys40(DTPA)]exendin = 0.2–0.8: and Rf 111In-
EDTA = 1).
Cell culture
The rat insulinoma cell line INS-1 (29) was maintained in RPMI-1640 medium 
supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 mM HEPES, 50 μM β-
mercaptoethanol, 1 mM sodium pyruvate, 100 units/ml penicillin and 100 μg/ml 
streptomycin, in a humidified 5% CO2 atmosphere at 37 °C. The cells were harvested by 
trypsinization with trypsin/EDTA.
Receptor binding assays
The 50% inhibitory concentration (IC50) was determined for [Lys40(natIn-DTPA)]exendin-3, 
[Lys40(natIn-DTPA)]exendin-4 and [Lys40(natIn-DTPA)]exendin(9-39) using suspensions of 
INS-1 cells. [Lys40(DTPA)]exendin-3 and [Lys40(DTPA)]exendin-4 were labelled with natIn 
by adding 21 μl natInCl3 (0.5 mM in 0.02 M HCl) to 105 μl 0.1 M MES buffer, pH 5.5 
containing 10 μg peptide, representing equimolar conditions. [Lys40(DTPA)]exendin(9-39) 
was labelled by adding 25 μl natInCl3 (0.5 mM in 0.02 M HCl) to 125 μl 0.1 M MES buffer, 
pH 5.5 containing 10 μg peptide. The reaction mixtures were incubated at room temperature 
for 20 min and 64 μl 1% Tween80 in PBS was added. Serial dilutions of [Lys40(natIn-
DTPA)]exendin-3, [Lys40(natIn-DTPA)]exendin-4 and [Lys40(natIn-DTPA)]exendin(9-39) 
were prepared in binding buffer (RPMI 1640 medium containing 1% BSA). INS-1 cells 
were resuspended in binding buffer to a concentration of 3 million cells/0.5 ml. After 10 min 
incubation on ice, [Lys40(natIn-DTPA)]exendin-3, [Lys40(natIn-DTPA)]exendin-4 and 
[Lys40(natIn-DTPA)]exendin(9-39) were added at final concentrations ranging from 0.10–
350 nM along with radiolabelled [Lys40(111In-DTPA)]exendin-3 (1,000 Bq). To prevent 
internalization, cells were incubated on ice for 4 h. The cell suspension was centrifuged at 
3,000 g for 5 min and the supernatant was discarded. The cell pellet was washed with 500 μl 
ice-cold PBS, centrifuged at 3,000 g for 5 min and the supernatant was discarded. The 
radioactivity in the cell pellet was determined in a gamma counter (Wizard, Wallac-Oy, 
Uppsala, Sweden) and the bound fraction was determined. Saturation binding assays were 
performed for [Lys40(111In-DTPA)]exendin-3, [Lys40(111In-DTPA)]exendin-4 and 
[Lys40(111In-DTPA)]exendin(9-39) in suspensions of INS-1 cells. Serial dilutions of the 
radiolabelled peptides, ranging from 0.1–125 nM, were added to 7 × 106 INS-1 cells in 600 
μl binding buffer. The cells were incubated on ice, to prevent internalization, for 4 h. After 
incubation the cells were centrifuged at 3,000 g for 5 min, the supernatant was discarded and 
the cells were washed with 500 μl ice-cold PBS. The radioactivity in the cell pellet was 
determined in a counter. The bound fraction (in receptors/cell) was plotted against the tracer 
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concentration added. In the scatchard plot the bound/free was plotted against the bound 
fraction and the dissociation constant (Kd) and the maximum number of binding sites was 
calculated by nonlinear regression using GraphPad Prism (version 4).
Internalization assay
The kinetics of internalization of [Lys40(111In-DTPA)]exendin-3, [Lys40(111In-
DTPA)]exendin-4 and [Lys40(111In-DTPA)]exendin(9-39) were determined using 
suspensions of INS-1 cells as described above. Approximately 1,000 Bq of 111In-labelled 
peptide (55 fmol) was added and incubated for 0.5, 1, 2 or 4 h at 37 °C. After incubation, the 
cells were centrifuged and the supernatant was discarded. The cells were washed twice with 
0.5 ml ice-cold PBS and subsequently 0.5 ml acid buffer (0.1 M acetic acid, 154 mM NaCl, 
pH 2.5) was added. After 10 min incubation at 4 °C, cells were spun down and the pellet 
was washed twice with ice-cold PBS. The radioactivity associated with the cell pellet 
(internalized fraction) and the supernatants (receptor-bound fraction) was determined.
Biodistribution studies
Animal experiments were performed after approval of the local ethical committee (RUDEC) 
for animal experiments (RUDEC). Six to eight weeks old female BALB/c nude mice were 
injected subcutaneously with 0.2 ml of a 1 × 107 cells/ml suspension of INS-1 cells. When 
the tumours were 2–5 mm in diameter, mice were randomly divided in groups of 5 mice. 
Mice were intravenously injected with 370 kBq (peptide dose: 20 pmol) of 111In-labelled 
[Lys40(DTPA)]exendin-3, [Lys40(DTPA)]exendin-4 or [Lys40(DTPA)]exendin(9-39) via a 
tail vein. At various time points (0.5, 1, 2 and 4 hours) after injection, mice were euthanized 
by CO2 suffocation and blood, tumour and relevant tissues (muscle, heart, lung, spleen, 
pancreas, kidney, liver, stomach and duodenum) were dissected, weighed and counted in a 
gamma counter. The percentage injected dose per gram tissue (%ID/g) was determined for 
each tissue. To determine whether the exendin uptake is GLP-1 receptor-mediated, a 100-
fold excess (2 nmol) of unlabelled [Lys40]exendin-3 was co-injected in a separate group of 
mice (n=5).
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Figure 1. 
Competition binding assay (IC50) of [Lys40(natIn-DTPA)]exendin-3, [Lys40(natIn-
DTPA)]exendin-4 and [Lys40(natIn-DTPA)]exendin(9-39). [Lys40(111In-DTPA)]exendin-3 
was used as tracer.
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Figure 2. 
Saturation binding assay and Scatchard plot (insert) of [Lys40(111In-DTPA)]exendin-3, 
[Lys40(111In-DTPA)]exendin-4 and [Lys40(111In-DTPA)]exendin(9-39).
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Figure 3. 
Internalization kinetics of [Lys40(111In-DTPA)]-exendin-3, [Lys40(111In-DTPA)]-exendin-4 
and [Lys40(111In-DTPA)]exendin(9-39). Specifically internalized (solid bars) and 
specifically cell surface bound (hatched bars) tracer are expressed in fmol.
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Figure 4. 
Biodistribution study of [Lys40(111In-DTPA)]exendin-3 (A), [Lys40(111In-DTPA)]exendin-4 
(B) and [Lys40(111In-DTPA)]exendin(9-39) (C) in BALB/c nude mice bearing a 
subcutaneous INS-1 tumour. Values are expressed as percentage injected dose per gram 
tissue (%ID/g). Blocking was performed by co-injection of a 100-fold molar excess of 
unlabelled [Lys40]exendin-3. Mice were dissected 4 hours after injection.
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Table 1
Amino acid sequence of GLP-1, exendin-3, exendin-4 and exendin(9-39). The homologous amino acids 
compared to GLP-1 are underlined.
Peptide Amino acid sequence
GLP-1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG
exendin-3 HSDGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
exendin-4 HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
exendin(9-39)  DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
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Table 2
IC50 values (with the 95% confidence interval in parenthesis) of [Lys40(natIn-DTPA)]exendin-3, [Lys40(natIn-
DTPA)]exendin-4 and [Lys40(natIn-DTPA)]exendin(9-39) determined in a competition binding assay in INS-1 
cells. The dissociation constant (Kd) and the Bmax (with the 95% confidence interval in parenthesis) of 
[Lys40(111In-DTPA)]exendin-3, [Lys40(111In-DTPA)]exendin-4 and [Lys40(111In-DTPA)]exendin(9-39) 
determined by a binding saturation experiment in INS-1 cells.
Compound IC50 (nM) Kd (nM) Bmax (receptors/cell)
[Lys40(DTPA)]exendin-3 13.5 (9.9 – 18.5) 8.7 (7.6 – 10.1) 26,000 (24 × 103 – 29 × 103)
[Lys40(DTPA)]exendin-4 13.4 (10.5 – 17.0) 17.6 (14.2 – 23.3) 41,000 (35 × 103 – 50 × 103)
[Lys40(DTPA)]exendin(9-39) 14.4 (4.8 – 43.2) 15.1 (6.9 – 80.7) 37,000 (13 × 103 – 60 × 103)
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